Discounted Cash Flow
Pharming Group N.V. ADR
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2018 | $135.1m | $857.0k | $38.0m | 0.6% | $0.04 |
| 2019 | $169.0m (25.1%) | $46.7m (5346.8%) | $64.1m (68.7%) | 27.6% (4254.6%) | $0.06 (41.5%) |
| 2020 | $185.7m (9.9%) | $38.6m (-17.3%) | $69.9m (9.0%) | 20.8% (-24.7%) | $0.05 (-12.1%) |
| 2021 | $198.9m (7.1%) | $23.1m (-40.2%) | $27.1m (-61.2%) | 11.6% (-44.2%) | $0.03 (-51.0%) |
| 2022 | $205.6m (3.4%) | $15.0m (-35.1%) | $21.1m (-22.2%) | 7.3% (-37.2%) | $0.02 (-16.0%) |
| 2023 | $245.3m (19.3%) | $-12.0m (-180.1%) | $-18.7m (-188.9%) | -4.9% (-167.2%) | $-0.02 (-176.2%) |
| 2024 | $297.2m (21.1%) | $-8.5m (29.3%) | $-2.6m (86.2%) | -2.9% (41.6%) | $-0.02 (-12.5%) |
| 2025 | $376.1m (26.6%) | $2.9m (133.6%) | $54.0m (2187.4%) | 0.8% (126.5%) | $0.00 (122.2%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.